Cardiovascular comorbidities are increased in US patients with haemophilia A: a retrospective database analysis. (29th November 2013)

• Record Type: Journal Article
• Authors: Pocoski, J.; Ma, A.; Kessler, C. M.; Boklage, S.; Humphries, T. J.
• Is Part Of: Haemophilia. Volume 20:Number 4(2014:Jul.)
• Page Start: 472
• Page End: 478
• Publication Date: 2013-11-29
• Subjects: Hemophilia -- Periodicals; 616.1572005
• DOI: 10.1111/hae.12339
• Languages: English
• ISSNs: 1351-8216

Abstract

<abstract abstract-type="main" id="hae12339-abs-0001"> <title>Summary</title> <p>There is conflicting evidence in the literature on whether individuals with haemophilia in the USA have greater, reduced, or similar risks for cardiovascular disease as the general population. This study evaluated the prevalence of cardiovascular comorbidities among USA males with haemophilia A, relative to an unaffected general male population with similar characteristics. Males with haemophilia A and continuous insurance coverage were identified by ICD‐9‐CM code 286.0 (1 January 2007–31 December 2009) using the <italic>MarketScan</italic><sup>®</sup> Commercial and Medicare Research Databases. Individuals with haemophilia A were exact matched 1:3 with males without a diagnosis of haemophilia A. The prevalence of cardiovascular comorbidities identified by ICD‐9‐CM code was determined for matched cohorts. Of the study population, 2506 were grouped in the haemophilia A cohort and 7518 in the general cohort. Proportions of individuals with haemorrhagic stroke (2.0% vs. 0.5%, <italic>P</italic> < 0.001), ischemic stroke (4.7% vs. 2.7%, <italic>P</italic> < 0.001), coronary artery disease (10.7% vs. 5.8%, <italic>P</italic> < 0.001), myocardial infarction (0.8% vs. 0.3%, <italic>P</italic> = 0.003), hypertension (22.6% vs. 15.5%, <italic>P</italic> < 0.001), hyperlipidaemia (15.9% vs. 11.9%, <italic>P</italic> < 0.001), arterial thrombosis (12.1% vs. 5.9%, <italic>P</italic> < 0.001), and venous thrombosis (4.4% vs. 1.1%, <italic>P</italic> < 0.001) were significantly greater for the haemophilia A cohort. Results were consistent across most age groups, and comorbidities appeared at an earlier age in those with haemophilia A than in the general population. Among the USA haemophilia A population cardiovascular comorbidities are more prevalent and they appear earlier in life in comparison to the general male population, suggesting the need for earlier, enhanced screening for age‐related comorbidities in the haemophilia community.</p> </abstract>